Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A novel adjuvant technology for use in vaccines and in antibody production that gives excellent immune responses with low manufacturing costs, and can be administered by a variety of routes More
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
New methods of diagnosing and monitoring the progression or response to therapy of subjects with autoimmune hepatitis More
Novel PIM 1 Kinase Inhibitor that Upregulates RUNX3 for the Treatment of Allergic Diseases More
Use of the Listeria Monocytogenes p60 Polypeptide and Variants for Stimulating NK cells More
Related Reports
Market Research Reports provided by reports.innovaro.com
May 2011 - 15 pages - $250
Aug 2011 - 8 pages - $75
Aug 2011 - 7 pages - $75
Dec 2010 - 37 pages - $500
Aug 2011 - 7 pages - $75
Aug 2011 - 7 pages - $75
Aug 2011 - 8 pages - $75
Jan 2010 - $75
Jan 2011 - 34 pages - $500
Nov 2010 - 40 pages - $500
Your selection
Browse By
- Industry sector
- Antibodies
- Antigens
- Biomarkers
- Cell lines
- Mouse models
- Reagents
- Vectors
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us